A study of Aldehyde dehydrogenase 2 polymorphism rs671, predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Mesothelioma; Squamous cell cancer; Thoracic neoplasms
- Focus Therapeutic Use
- 08 Nov 2021 New trial record